Colorado is currently home to 1906 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The Effects of Orchiectomy and Age on Vascular and Metabolic Health in Older Versus Younger Transgender Women
NCT05195164
Recruiting
This study plans to learn more about differences in heart disease risk after gender-affirming orchiectomy (i.e., testes removal) in older transgender (trans) women compared to younger trans women.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
03/06/2023
Locations: University of Colorado, Aurora, Colorado
Conditions: Transgender, Gender Identity, Vascular Stiffness, Vascular Inflammation, Insulin Sensitivity, Blood Pressure, Lipid Disorder, Appetitive Behavior
Register for Updates
Premature Discontinuation of Contraceptive Implants
NCT04828824
Recruiting
To compare rates of etonogestrel implant discontinuation in implant initiators who are given advance provision of combined oral contraceptive pills (COCs) and a bleeding rescue regimen (COCR intervention) to participants given standard counseling (comparator).
Gender:
Female
Ages:
Between 14 years and 23 years
Trial Updated:
03/03/2023
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Contraception Behavior
Register for Updates
Non-invasive Evaluation of Upper and Lower Body Function With Showmotion
NCT04137835
Recruiting
It is very important to understand joint and body kinematics and muscles activity in clinical settings, which is relevant to identify issues related to the spine, the upper and lower limbs due to injury. In this study, the investigators will use an innovative platform, Showmotion to establish baseline of shoulder, hip, knee and spine kinematics and muscles activity from 60 healthy volunteers.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2023
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Osteoarthritis, Hip, Osteoarthritis, Knee, Osteoarthritis, Spine
Register for Updates
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT01773278
Recruiting
Patients with biochemically confirmed SLOS are being treated with cholesterol supplementation and antioxidant medication. They are carefully monitored with visits to clinic, laboratory testing including cholesterol and 7-dehydrocholesterol levels, vitamin levels, blood counts and liver and kidney function. On a serial basis, no more often than once a year, the patients undergo a series of tests under anesthesia, including electroretinogram (ERG), brainstem audiometry (ABR), and ophthalmologic ex... Read More
Gender:
All
Ages:
65 years and below
Trial Updated:
03/02/2023
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Smith-Lemli-Opitz Syndrome, Cone-Rod Dystrophy, Hearing Loss
Register for Updates
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
NCT03787602
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Merkel Cell Carcinoma
Register for Updates
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
NCT03061305
Recruiting
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials. The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2023
Locations: SCL Health, Broomfield, Colorado
Conditions: Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma
Register for Updates
Randomized Therapy In Status Epilepticus
NCT04391569
Recruiting
This study will evaluate the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).
Gender:
All
Ages:
12 years and above
Trial Updated:
02/22/2023
Locations: Marinus Research Site, Aurora, Colorado
Conditions: Status Epilepticus
Register for Updates
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348
Recruiting
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2023
Locations: UCHealth Cancer Center - Harmony Campus, Fort Collins, Colorado
Conditions: Multiple Myeloma
Register for Updates
Natural Killer Cell (CYNK-001) Infusions in Adults With AML
NCT04310592
Recruiting
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/15/2023
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
Register for Updates
A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
NCT03561259
Recruiting
The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in combination with Vorinostat in patients with Recurrent or Progressive neuroblastoma
Gender:
All
Ages:
1 year and above
Trial Updated:
02/15/2023
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Neuroblastoma, Neuroectodermal Tumors, Neoplasms
Register for Updates
Clinical Evaluation of the Zynex Monitoring System, Model CM-1600
NCT05740644
Recruiting
This is a prospective, single-arm, non-randomized, non-controlled single-center study for the evaluation of the Zynex CM-1600 in 20 healthy adults undergoing a manual blood loss of up to 500mL followed by an infusion of 1 liter of normal saline.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/13/2023
Locations: Clinimark, Louisville, Colorado
Conditions: Fluid Loss
Register for Updates
Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone
NCT05726903
Recruiting
Recommendations regarding contraceptive counseling and reproductive health differ amongst transgender and gender diverse (TGD) youth compared to cis-gender youth. Limited existing literature demonstrates the need for contraceptive counseling that moves beyond cis- and heteronormative assumptions that start with pregnancy prevention and address concerns at the intersection of gender identity. The Investigator's qualitative study will focus on creating best practices regarding equitable contracep... Read More
Gender:
Female
Ages:
Between 15 years and 21 years
Trial Updated:
02/13/2023
Locations: Comprehensive Women's Health Center, Denver, Colorado
Conditions: Gender Dysphoria, Adolescent
Register for Updates